NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Julie & Holleman LLP, a top-tier shareholder rights firm, is investigating Abbott's proposed $21 billion acquisition of Exact Sciences Corp. (NASDAQ: EXAS). Julie & Holleman has already identified conflicts and believes the $105 per share deal price may be too low.

Exact Sciences is investing heavily in R&D and commercial capabilities to boost Cologuard adoption, but competition and macro pressures cloud the outlook.

Exploring the Fund's Recent Portfolio Adjustments Vanguard Health Care Fund (Trades, Portfolio) recently submitted its N-PORT filing for the third quarter of 2

Bamco Inc. NY grew its holdings in Exact Sciences Corporation (NASDAQ: EXAS) by 26.4% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,861,341 shares of the medical research company's stock after purchasing an additional 388,627 shares during the quarter. Bamco

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the first clinical study results from its Oncodetect® molecular residual disease (MRD) test in breast cancer. Findings from the NSABP B-59 substudy, conducted in collaboration with the NSABP Foundation and the German Breast Group (GBG), demonstrated that the Oncodetect test strongly predicts distant recurrence following surgery in patients with early.

First Trust Advisors LP cut its position in shares of Exact Sciences Corporation (NASDAQ: EXAS) by 2.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 729,930 shares of the medical research company's stock after selling 18,983 shares during the

Baird Financial Group Inc. reduced its holdings in shares of Exact Sciences Corporation (NASDAQ: EXAS) by 9.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 280,348 shares of the medical research company's stock after selling 30,218 shares during the quarter.

Fisher Asset Management LLC trimmed its position in Exact Sciences Corporation (NASDAQ: EXAS) by 15.0% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 158,029 shares of the medical research company's stock after selling 27,925 shares during the period. Fisher Asset Management LLC owned about

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock?

As of Dec. 2, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.